Pathways with alterations throughout disease progression in PD included EIF2 signaling (BH-FDR = 0.00000047), breast cancer regulation by Stathim 1 (BH-FDR = 0.000051), regulation of eIF4 and p70S6K signaling (BH-FDR = 0.00014), dopamine-DARPP32 feedback in cAMP signaling (BH-FDR = 0.00018) and mTOR signaling (BH-FDR = 0.00019). This evidence concerns the gene PPP1R1B and breast carcinoma.